Pure Global
NCT05999669

Predictive Value of the Global Limb Anatomic Staging System (GLASS) in Patients With Critical Limb-threatening Ischemia

Assessing the Predictive Value of the Global Limb Anatomic Staging System (GLASS) in EndoVascular Therapy (EVT) of Infrainguinal Lesions in Patients With Critical Limb-threatening Ischemia (CLTI): the GLASS-EVT Study
RenJi Hospital·ClinicalTrials.gov·otherNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral Arterial Disease
Drug/Device/Intervention
GLASS staging
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
RenJi Hospital
Timeline & enrollment
Phase
N/A
Start date
Aug 20, 2023
End date
Dec 31, 2027
Enrollment
2000 participants
Primary outcome

Rate of freedom from major adverse events (MAEs)

Summary

The Global Vascular Guideline on chronic limb threatening ischemia (CLTI) proposes the Global
 Limb Anatomic Staging System (GLASS), a new angiographic scoring system to quantify the
 anatomic severity of infrainguinal disease in CLTI patients. However, GLASS validation still
 needs to be completed, and the infrapopliteal (IP) target artery pathway (TAP) was easily
 influenced by the procedures. Thus the IP target artery could be selected either as the least
 diseased artery based on angiography or prospectively based on the angiosome concept. So the
 investigators aim to evaluate its correlation with clinical outcomes after revascularization.

ICD-10 classifications
Peripheral vascular disease, unspecifiedOther peripheral vascular diseasesOther specified peripheral vascular diseasesPeripheral angiopathy in diseases classified elsewhereOther congenital malformations of peripheral vascular system
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05999669
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05999669 through Pure Global AI's free database. This phase not specified trial is sponsored by RenJi Hospital and is currently Not yet recruiting. The study focuses on Peripheral Arterial Disease. Target enrollment is 2000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.